The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended authorization for five new drugs, including conditional approval of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for noncirrhotic metabolic dysfunction-associated steatohepatitis and Ogsiveo (nirogacestat) for non-malignant desmoid tumors. The committee also initiated re-examination of Eli Lilly’s Alzheimer’s drug Kisunla. These recommendations mark significant regulatory progress reflecting ongoing approvals and reassessments in the EU pharmaceutical landscape, aligning closely with recent FDA decisions.